Traws Pharma, Inc.
TRAW
$1.51
-$0.02-1.31%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| SG&A Expenses | 35.13% | 20.72% | 19.62% | 23.44% | 7.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.47% | 11.58% | -6.60% | -10.33% | 3.38% |
| Operating Income | -22.72% | -11.70% | 6.67% | 10.44% | -3.42% |
| Income Before Tax | -778.84% | -597.51% | -557.53% | 11.94% | 0.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -778.84% | -597.51% | -557.53% | 11.94% | 0.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -778.84% | -597.51% | -557.53% | 11.94% | 0.08% |
| EBIT | -22.72% | -11.70% | 6.67% | 10.44% | -3.42% |
| EBITDA | -22.76% | -11.72% | 6.69% | 10.46% | -3.41% |
| EPS Basic | -386.28% | -487.25% | -455.35% | 12.28% | 0.43% |
| Normalized Basic EPS | -33.18% | -5.20% | 10.98% | 12.28% | 0.43% |
| EPS Diluted | -386.28% | -485.44% | -453.69% | 12.55% | 0.76% |
| Normalized Diluted EPS | -33.18% | -5.20% | 10.98% | 12.28% | 0.43% |
| Average Basic Shares Outstanding | 75.54% | 8.98% | 5.48% | 0.40% | 0.36% |
| Average Diluted Shares Outstanding | 75.54% | 8.98% | 5.48% | 0.40% | 0.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |